VMC Members[close]

Login

Not yet a member?

Stay up to date with
the latest health news




Are you a Health Professional?

Read more detailed and referenced information written by Australian health professionals, make sure you select health professional in the signup form!

Targeting serotonin to promote repair of a damaged liver

Publishing in the leading medical journal Nature Medicine, a team led by Newcastle University academics have identified serotonin receptors which can be targeted with drugs to enhance the natural healing properties of the liver.

In liver disease, extent of tissue damage depends on the balance between the generation of scar tissue and the regeneration of new liver cells. In a significant minority of people who get injury to their organs instead of repairing them, they form scars. This can progress to chronic liver disease and cirrhosis where the scarring is so extensive the liver is unable to clean blood or produce vital hormones and clotting factors. Liver scars also provide an ideal environment for the development of cancers.

Publishing in Nature Medicine and showcased in Nature Research Highlights, the paper describes how working in mouse models the team were able to tip this balance to favour healthy tissue regeneration and block scarring by manipulating the actions of serotonin - the "happy" drug.

Normally when a liver is injured – by a virus such as Hepatitis C or B, by alcohol, environmental factors or by a metabolic or autoimmune condition – specialised blood cells known as platelets make general repairs and secrete serotonin.

However, the team found that when scar-forming cells - Hepatic stellate cells (HSC) – are present they are instructed by the serotonin to make more scar tissue and switch off the healthy regeneration.
Identifying the receptor called 5-HT2B through which serotonin instructs the scar forming cells to switch off regeneration, they found that this resulted in less scarring and more regeneration.

Of the work funded by the Medical Research Council and the Wellcome Trust, lead author, Professor Derek Mann said; "These are promising results in mouse models of liver disease and suggest that chemicals targeting 5-HT2B , which are currently in clinical trials for mood disorders and pulmonary hypertension might also have an application in the treatment of chronic liver disease."

The group believe the mechanism may also be found in other organs and offers an exciting opportunity for study in the future.


(Source: Newcastle University: Nature Medicine)


calendar icon Article Date: 28/12/2011

 

Related Diseases

 

Related Articles:


Connect

Sign up for free newsletter Sign up for free newsletters
News RSS feeds Subscribe to RSS feeds
Discuss on Forum Discuss on Forum
share this page with others

 

Article Comments

Add your comment to this article





 Change Code


 Enter the above security Code

User-generated Content Guidelines

Rate this article

Current Sponsors
About Virtualmedicalcentre.com

Virtual Medical Centre

Australia’s leading source for trustworthy medical information written by health professionals.

Please be aware that we do not give advice on your individual medical condition,
if you want advice please see your treating physician.

Virtual Medical Centre © 2002 - 2013 | Privacy Policy Last updated 20 May 2013

Parenting information is available at Parenthub.com.au

^ Back to Top
 
Partners and Accreditations
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.
Health insite MindHealth Connect Pregnancy Birth and Baby
PANDORA is a digital archive dedicated to the preservation of and long term access to Australian online electronic publications of national significance Parenthub.com.au for parenting information
For banner advertising
Multi Channel Network
Website and videos by
Titan Web
Titan Web Clients
Web Design Perth